硕肯生物硕肯生物Soken.bio
查看试用产品 →开放浏览 · 登录后申请
人 LILRB1 抗体对
试剂盒

人 LILRB1 抗体对

01AB00872

Leukocyte immunoglobulin like receptor B1 (LILRB1) is an inhibitory receptor expressed on various immune cells, including myeloid cells, NK cells, and subsets of T and B cells. It contains four extracellular immunoglobulin-like domains and intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). LILRB1 binds to MHC class I molecules, including HLA-G, and transduces negative signals that suppress immune responses and cytotoxicity. Upon activation, LILRB1 recruits phosphatases like SHP-1 and CSK, which dephosphorylate key kinases involved in immune cell activation. LILRB1 plays crucial roles in immune tolerance, regulating phagocytosis, and modulating NK cell and T cell functions. In pathological conditions, LILRB1 has been implicated in cancer progression, where its expression on NK cells correlates with decreased cytotoxicity in breast cancer. Additionally, some pathogens exploit LILRB1 to evade immune responses.

Human
规格起售价
登录后可查看

技术参数

靶点基因名
LILRB1
基因别名
ILT2; LIR1; MIR7
蛋白别名
leukocyte immunoglobulin like receptor B1; LILRB1
UniProt
Q8NHL6
物种
Human

产品详情

靶点名称
LILRB1
蛋白名称
leukocyte immunoglobulin like receptor B1
蛋白别名
Leukocyte immunoglobulin-like receptor subfamily B member 1; LIR-1; Leukocyte immunoglobulin-like receptor 1; CD85 antigen-like family member J; Immunoglobulin-like transcript 2; ILT-2; Monocyte/macrophage immunoglobulin-like receptor 7; MIR-7; CD antigen CD85j
靶点基因名
LILRB1
基因别名
ILT2; LIR1; MIR7
UniProt
Q8NHL6
来源物种
Homo sapiens (Human)
物种反应性
Human

背景介绍

Leukocyte immunoglobulin like receptor B1 (LILRB1) is an inhibitory receptor expressed on various immune cells, including myeloid cells, NK cells, and subsets of T and B cells. It contains four extracellular immunoglobulin-like domains and intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs). LILRB1 binds to MHC class I molecules, including HLA-G, and transduces negative signals that suppress immune responses and cytotoxicity. Upon activation, LILRB1 recruits phosphatases like SHP-1 and CSK, which dephosphorylate key kinases involved in immune cell activation. LILRB1 plays crucial roles in immune tolerance, regulating phagocytosis, and modulating NK cell and T cell functions. In pathological conditions, LILRB1 has been implicated in cancer progression, where its expression on NK cells correlates with decreased cytotoxicity in breast cancer. Additionally, some pathogens exploit LILRB1 to evade immune responses.